ZA200007254B - Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release. - Google Patents

Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release. Download PDF

Info

Publication number: ZA200007254B
Authority: ZA; South Africa
Prior art keywords: compound; formula; alkyl; compound according; aryl
Prior art date: 1998-06-22

Application number

ZA200007254A

Other languages

English (en)

Inventor

Andrew Faller

David T Macpherson

Peter H Milner

Jayshree Mistry

John Gerard Ward

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

2000-12-07

Publication date

2002-02-07

2000-12-07 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2002-02-07 Publication of ZA200007254B publication Critical patent/ZA200007254B/en

Links

238000004519 manufacturing process Methods 0.000 title claims description 8
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 title description 22
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 title description 21
241000282414 Homo sapiens Species 0.000 title description 12
239000003112 inhibitor Substances 0.000 title description 6
239000002253 acid Substances 0.000 title description 5
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims description 55
125000003118 aryl group Chemical group 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 16
-1 2-naphthylmethyl Chemical group 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
208000023275 Autoimmune disease Diseases 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
208000026935 allergic disease Diseases 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 7
238000012261 overproduction Methods 0.000 claims description 7
238000011321 prophylaxis Methods 0.000 claims description 7
125000006239 protecting group Chemical group 0.000 claims description 7
206010020751 Hypersensitivity Diseases 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 6
230000007815 allergy Effects 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
125000005002 aryl methyl group Chemical group 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
125000000623 heterocyclic group Chemical group 0.000 description 11
108700012920 TNF Proteins 0.000 description 10
108050007852 Tumour necrosis factor Proteins 0.000 description 10
102000018594 Tumour necrosis factor Human genes 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
230000001404 mediated effect Effects 0.000 description 7
125000003545 alkoxy group Chemical group 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
210000001616 monocyte Anatomy 0.000 description 6
230000007017 scission Effects 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
125000004414 alkyl thio group Chemical group 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
239000002585 base Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
150000002431 hydrogen Chemical group 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
244000045947 parasite Species 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
108010073816 IgE Receptors Proteins 0.000 description 1
102000009438 IgE Receptors Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102100022297 Integrin alpha-X Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000017306 interleukin-6 production Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
150000002690 malonic acid derivatives Chemical class 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000203 mixture Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000012423 response to bacterium Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

ZA200007254A 1998-06-22 2000-12-07 Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release. ZA200007254B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9813451.3A GB9813451D0 (en)	1998-06-22	1998-06-22	Novel compounds

Publications (1)

Publication Number	Publication Date
ZA200007254B true ZA200007254B (en)	2002-02-07

Family

ID=10834177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200007254A ZA200007254B (en)	1998-06-22	2000-12-07	Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release.

Country Status (32)

Country	Link
US (1)	US6458779B1 (de)
EP (1)	EP1089963B1 (de)
JP (1)	JP2002518470A (de)
KR (1)	KR20010053076A (de)
CN (1)	CN1306508A (de)
AP (1)	AP2000002001A0 (de)
AR (1)	AR029303A1 (de)
AT (1)	ATE269296T1 (de)
AU (1)	AU744801B2 (de)
BG (1)	BG105154A (de)
BR (1)	BR9911423A (de)
CA (1)	CA2335513A1 (de)
DE (1)	DE69918113T2 (de)
DK (1)	DK1089963T3 (de)
EA (1)	EA200100065A1 (de)
ES (1)	ES2222711T3 (de)
GB (1)	GB9813451D0 (de)
HK (1)	HK1025894A1 (de)
HU (1)	HUP0102776A3 (de)
ID (1)	ID27413A (de)
IL (1)	IL139738A (de)
MY (1)	MY121785A (de)
NO (1)	NO20006349D0 (de)
NZ (1)	NZ508229A (de)
OA (1)	OA11639A (de)
PL (1)	PL345038A1 (de)
PT (1)	PT1089963E (de)
SI (1)	SI1089963T1 (de)
SK (1)	SK19562000A3 (de)
TR (1)	TR200003877T2 (de)
WO (1)	WO1999067201A1 (de)
ZA (1)	ZA200007254B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020082200A1 (en) *	1994-07-13	2002-06-27	Smithkline Beecham P.1.C.	Use of inhibitors of human S-CD23
US6716878B1 (en) *	1999-04-09	2004-04-06	Vernalis (Oxford) Limited	Antimicrobial agents
GB9925470D0 (en) *	1999-10-27	1999-12-29	Smithkline Beecham Plc	Novel compounds
GB9929527D0 (en) *	1999-12-14	2000-02-09	Smithkline Beecham Plc	Novel compounds
JP2003523994A (ja) *	2000-02-24	2003-08-12	スミスクラインビーチャムパブリックリミテッドカンパニー	新規ｃｄ２３インヒビター
WO2004076386A2 (en)	2003-02-25	2004-09-10	Topotarget Uk Limited	Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9223904D0 (en) *	1992-11-13	1993-01-06	British Bio Technology	Inhibition of cytokine production
GB9414157D0 (en) *	1994-07-13	1994-08-31	Smithkline Beecham Plc	Medical use
GB9507799D0 (en)	1995-04-18	1995-05-31	British Biotech Pharm	Metalloproteinase inhibitors
US5691381A (en) *	1995-04-18	1997-11-25	The Dupont Merck Pharmaceutical Company	Hydroxamic and carbocyclic acids as metalloprotease inhibitors
GB9513331D0 (en) *	1995-06-30	1995-09-06	British Biotech Pharm	Matrix metalloproteinase inhibitors
AU7335496A (en) *	1995-10-23	1997-05-15	Sankyo Company Limited	Hyroxamic acid derivatives
GB9609794D0 (en) *	1996-05-10	1996-07-17	Smithkline Beecham Plc	Novel compounds
WO1998043959A1 (en) *	1997-03-28	1998-10-08	Zeneca Limited	Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor

1998
- 1998-06-22 GB GBGB9813451.3A patent/GB9813451D0/en not_active Ceased
1999
- 1999-06-22 CA CA002335513A patent/CA2335513A1/en not_active Abandoned
- 1999-06-22 ID IDW20002683A patent/ID27413A/id unknown
- 1999-06-22 CN CN99807653A patent/CN1306508A/zh active Pending
- 1999-06-22 BR BR9911423-2A patent/BR9911423A/pt not_active IP Right Cessation
- 1999-06-22 NZ NZ508229A patent/NZ508229A/en unknown
- 1999-06-22 SK SK1956-2000A patent/SK19562000A3/sk unknown
- 1999-06-22 KR KR1020007014549A patent/KR20010053076A/ko not_active Application Discontinuation
- 1999-06-22 AT AT99928068T patent/ATE269296T1/de not_active IP Right Cessation
- 1999-06-22 DE DE69918113T patent/DE69918113T2/de not_active Expired - Fee Related
- 1999-06-22 EA EA200100065A patent/EA200100065A1/ru unknown
- 1999-06-22 SI SI9930648T patent/SI1089963T1/xx unknown
- 1999-06-22 MY MYPI99002571A patent/MY121785A/en unknown
- 1999-06-22 AP APAP/P/2000/002001A patent/AP2000002001A0/en unknown
- 1999-06-22 IL IL13973899A patent/IL139738A/en not_active IP Right Cessation
- 1999-06-22 ES ES99928068T patent/ES2222711T3/es not_active Expired - Lifetime
- 1999-06-22 DK DK99928068T patent/DK1089963T3/da active
- 1999-06-22 AR ARP990102994A patent/AR029303A1/es unknown
- 1999-06-22 JP JP2000555856A patent/JP2002518470A/ja active Pending
- 1999-06-22 WO PCT/GB1999/001954 patent/WO1999067201A1/en not_active Application Discontinuation
- 1999-06-22 AU AU45195/99A patent/AU744801B2/en not_active Ceased
- 1999-06-22 EP EP99928068A patent/EP1089963B1/de not_active Expired - Lifetime
- 1999-06-22 PL PL99345038A patent/PL345038A1/xx not_active Application Discontinuation
- 1999-06-22 US US09/701,946 patent/US6458779B1/en not_active Expired - Fee Related
- 1999-06-22 HU HU0102776A patent/HUP0102776A3/hu unknown
- 1999-06-22 TR TR2000/03877T patent/TR200003877T2/xx unknown
- 1999-06-22 PT PT99928068T patent/PT1089963E/pt unknown
- 1999-06-22 OA OA1200000359A patent/OA11639A/en unknown
2000
- 2000-12-07 ZA ZA200007254A patent/ZA200007254B/en unknown
- 2000-12-13 NO NO20006349A patent/NO20006349D0/no not_active Application Discontinuation
2001
- 2001-01-15 BG BG105154A patent/BG105154A/bg unknown
- 2001-09-14 HK HK01106515A patent/HK1025894A1/xx unknown

Also Published As

Publication number	Publication date
WO1999067201A1 (en)	1999-12-29
TR200003877T2 (tr)	2001-06-21
CA2335513A1 (en)	1999-12-29
HUP0102776A3 (en)	2002-11-28
EP1089963B1 (de)	2004-06-16
MY121785A (en)	2006-02-28
SI1089963T1 (en)	2004-12-31
BR9911423A (pt)	2001-03-13
AU4519599A (en)	2000-01-10
DK1089963T3 (da)	2004-10-18
GB9813451D0 (en)	1998-08-19
IL139738A (en)	2005-12-18
EP1089963A1 (de)	2001-04-11
KR20010053076A (ko)	2001-06-25
BG105154A (bg)	2001-08-31
NO20006349L (no)	2000-12-13
ATE269296T1 (de)	2004-07-15
ID27413A (id)	2001-04-05
AU744801B2 (en)	2002-03-07
NO20006349D0 (no)	2000-12-13
ES2222711T3 (es)	2005-02-01
PL345038A1 (en)	2001-11-19
PT1089963E (pt)	2004-10-29
AP2000002001A0 (en)	2000-12-31
JP2002518470A (ja)	2002-06-25
SK19562000A3 (sk)	2001-08-06
HK1025894A1 (en)	2000-12-01
HUP0102776A2 (hu)	2001-12-28
US6458779B1 (en)	2002-10-01
DE69918113D1 (de)	2004-07-22
OA11639A (en)	2004-11-27
EA200100065A1 (ru)	2001-06-25
DE69918113T2 (de)	2005-07-07
AR029303A1 (es)	2003-06-25
NZ508229A (en)	2003-12-19
CN1306508A (zh)	2001-08-01
IL139738A0 (en)	2002-02-10

Publication	Publication Date	Title
US6242467B1 (en)	2001-06-05	Compounds
JP2768554B2 (ja)	1998-06-25	金属タンパク質加水分解酵素阻害剤であるヒドロキサム酸誘導体
US5763621A (en)	1998-06-09	Metalloproteinase inhibitors
US5525629A (en)	1996-06-11	Inhibition of cytokine production
US5442110A (en)	1995-08-15	Hydroxamic acid derivative
EP0918747B1 (de)	2003-08-06	Inhibitoren der produktion von s-cd23 und der secretion von tnf
AU736754B2 (en)	2001-08-02	Novel piperidineketocarboxylic acid derivatives, their preparation and use
SK94196A3 (en)	1997-03-05	Metalloproteinase inhibitors, pharmaceutical compositions containing them, manufacturing process thereof and their use
JPH08503475A (ja)	1996-04-16	抗変性活性剤としてのカルボキシ−ペプチジル誘導体
ZA200007254B (en)	2002-02-07	Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release.
CA2092414A1 (en)	1992-04-12	N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
US20030195191A1 (en)	2003-10-16	N-sulfonyl hydroxamic acid derivatives as inhibitors of cd23
BG60346B2 (bg)	1994-06-30	Метод за получаване на z-2-ациламино-3-монозаместени пропеноати
AU725056B2 (en)	2000-10-05	Hydroxamic acid based collagenase inhibitors
US6090785A (en)	2000-07-18	Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
WO1997043250A1 (en)	1997-11-20	Hydroxamic acid based inhibitors of the formation of cd23 and tnf
US20040225006A1 (en)	2004-11-11	(Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates
AU1389501A (en)	2001-05-08	Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23
CA2374555A1 (en)	2000-12-21	Thiol derivative, metallo-beta-lactamase inhibitors
US20040209822A1 (en)	2004-10-21	Novel compounds
WO2001044221A1 (en)	2001-06-21	Hydroxamic acid derivatives as inhibitors of human cd23 and of the tnf release
JPS6140292A (ja)	1986-02-26	３−（アルキニルアルキルオキシ）セフアロスポリン類
AU5606300A (en)	2001-01-02	Thiol derivative, metallo-beta-lactamase inhibitors